UCLA Personalized Cancer Vaccine Offers New Hope for Glioblastoma Patients

Key Clinical Takeaways:

• Researchers utilize a patient’s own cells, isolated from their blood and exposed to tumor proteins, to create a bespoke vaccine that stimulates a targeted immune response.
• Clinical trials have identified a group of glioblastoma patients who have experienced long-term survival, a notable outcome for this devastating disease.
• Future research is shifting toward combination therapies, pairing vaccines with immune checkpoint inhibitors to produce stronger and more lasting responses.

UCLA Vaccine Research Targets Glioblastoma

For over two decades, neurosurgeon Dr. Linda Liau and tumor immunologist Dr. Robert Prins have led research at the UCLA Health Jonsson Comprehensive Cancer Center focused on glioblastoma. This malignancy is characterized by rapid growth and an ability to evade standard treatments like surgery, chemotherapy, and radiation. UCLA Health reported that the team developed a personalized vaccine that uses the body’s own immune system to recognize and attack brain tumors.

Patient Outcomes in Clinical Trials

Jamil Newirth, diagnosed with glioblastoma at age 32, serves as a clinical example of the vaccine’s potential. After being told he had about 17 months to live, he enrolled in a UCLA clinical trial. Fourteen years later, Newirth remains a practicing attorney in Maui.

He is among a group of patients who have experienced long-term survival after receiving the personalized vaccine. Dr. Liau noted, “He and other patients like him are what inspires me to go to work each day and to maintain hope that immunotherapy could potentially lead to a cure for brain cancer someday.”

Biological Mechanism of the Vaccine

The vaccine functions by collecting tumor tissue during surgical resection and isolating cells from the patient’s blood. These cells serve as messengers, which researchers expose to tumor proteins in a laboratory setting.

Once injected back into the patient, the trained cells help activate an immune response directed against the tumor. Unlike preventative vaccines, this therapeutic approach is designed to help the immune system fight an existing cancer, with each vaccine tailored to the individual patient’s tumor.

Challenges in Treatment Response

While the vaccine has produced long-term survival in some participants, the encouraging responses have been seen in some patients. Researchers are now investigating whether combining the vaccine with other immunotherapies could produce stronger and more lasting responses.

Transitioning to Combination Immunotherapy

The research team is now testing whether combining the vaccine with immune checkpoint inhibitors yields stronger results. While checkpoint inhibitors have transformed treatment for several cancers, they have shown limited success against glioblastoma when used alone. “The future of glioblastoma treatments is going to be these combination approaches,” said Dr. Liau.

Expanding Research to Rare Gliomas

Innovation continues through the Pediatric Brain Tumor Program at UCLA Health, where Dr. Anthony Wang is leading a clinical trial testing a new vaccine for H3 G34-mutant diffuse hemispheric glioma, a rare and aggressive type of brain cancer that primarily affects adolescents and young adults.

The trial aims to evaluate the vaccine for patients facing these specific genetic mutations.

Disclaimer: The information provided in this article is for educational and scientific communication purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider regarding any medical condition, diagnosis, or treatment plan.